Chaft, Jamie Erin

Publications

Sort by

Co-Author Network

selected publications

Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease. Annals of surgery. 2019 Academic Article GET IT
Times cited: 24
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 98
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer research. 2018 Academic Article GET IT
Times cited: 226
Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 88
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 167
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 122
Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. The Journal of thoracic and cardiovascular surgery. 2018 Academic Article GET IT
Times cited: 30
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 184
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Information Resource GET IT
Times cited: 54
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England journal of medicine. 2018 Article GET IT
Times cited: 43
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 379
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 351
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 272
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 42
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 644
Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer. The Annals of thoracic surgery. 2018 Academic Article GET IT
Times cited: 21
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung cancer (Amsterdam, Netherlands). 2018 Academic Article GET IT
Times cited: 39
Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. Advances in radiation oncology. 2018 Academic Article GET IT
Times cited: 36
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1448
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 780
Immunotherapy in surgically resectable non-small cell lung cancer. Journal of thoracic disease. 2018 Information Resource GET IT
Times cited: 51
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 1062
KEYNOTE-024: Unlocking a pathway to lung cancer cure?. The Journal of thoracic and cardiovascular surgery. 2017 Editorial Article GET IT
Times cited: 5
Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy. Clinical lung cancer. 2017 Academic Article GET IT
Times cited: 11
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. Translational lung cancer research. 2017 Information Resource GET IT
Times cited: 23
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 45
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 491
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 503
Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery. Clinical lung cancer. 2017 Academic Article GET IT
Times cited: 16
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 862
Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma. Oncotarget. 2016 Academic Article GET IT
Times cited: 19
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers. Lung cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 47
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 560
Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer. The Annals of thoracic surgery. 2016 Academic Article GET IT
Times cited: 27
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 36
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Information Resource GET IT
Times cited: 102
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 82
Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 189
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clinical lung cancer. 2014 Academic Article GET IT
Times cited: 36
Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014 Academic Article GET IT
Times cited: 644
Chemotherapy for lung cancers: here to stay. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Information Resource GET IT
Times cited: 5
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Science translational medicine. 2013 Academic Article GET IT
Times cited: 469
Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 1
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 115
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 14
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Molecular cancer therapeutics. 2013 Academic Article GET IT
Times cited: 399
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 26
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 128
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012 Academic Article GET IT
Times cited: 93
Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 41
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 2012 Academic Article GET IT
Times cited: 127
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 409
The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. Journal of the National Comprehensive Cancer Network : JNCCN. 2012 Information Resource GET IT
Times cited: 52
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Molecular cancer therapeutics. 2011 Academic Article GET IT
Times cited: 182
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 377
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 61
Genetics of vascular anomalies: an update. Lymphatic research and biology. 2003 Information Resource GET IT
Times cited: 2
Prenatal diagnosis of vascular anomalies: update and review of the literature. Lymphatic research and biology. 2003 Information Resource GET IT
Times cited: 5

more ...

less ...

Background

education and training

M.D., New York University School of Medicine 2006
B.A., Princeton University 2002

Contact

full name

Jamie Erin Chaft

VIVO Weill Cornell Medical College

Jamie Erin Chaft Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name